|
I was reading an article by Edith Perez on line yesterday (which, of course I now cannot find when I need it) but it gave the most precise breakdown I have seen for what AI's can do to help prognosis. The article addressed the different drugs individually. What was surprising to me was the stat for the benefit of Femara on recurrence risk: 60% overall relative reduction, but 14% relative reduction for distant recurrence. The main benefit of these drugs is preventing local recurrence or a new cancer from starting. While there is some protection against mets, it is nowhere near as strong. As I am considering stopping AI treatment early, this is an important consideration for me. I will continue to noodle around on line and will post a link to the article if I can find it again.
Hopeful
|